亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Novel Inhibitor of HIV Replication

技術優勢
Structurally unrelated to current anti-viral therapiesHas potent broad spectrum antiviral activity (e.g. treatment of HIV and various enteroviruses)May act through a potentially novel mechanism of action
技術應用
Treatment for HIV-1 infectionTreatment for a variety of enterovirus infectionsMaybe used to treat drug-resistant variants of HIV-1 infection
詳細技術說明
UCLA researchers led by Profs. Paul Krogstad and Jun Zuo have identified a novel small molecule inhibitor of HIV-1 replication, as well as a broad spectrum anti-viral for the treatment of a variety of enteroviruses. Additionally this molecule is structurally unrelated to current antiviral therapeutics, and potentially utilizes a novel mechanism of action, and may be useful for variants of HIV that are resistant to current therapies.
*Abstract
UCLA researchers in the David Geffen School of Medicine have discovered a new small molecule inhibitor for HIV-1 replication.
*Principal Investigation

Name: Paul Krogstad

Department:


Name: Jun Zuo

Department:

其他

State Of Development

Researchers have tested this inhibitor in models of HIV-1 and enterovirus infection.


Background

Virus-borne diseases represent a significant proportion of infectious diseases worldwide. These diseases, including HIV the virus that causes AIDS which affect millions of people, and are often life-threatening, and have enormous economic impacts; the global market for HIV is estimated at ~$11 billion. Thus, drugs targeting a broad spectrum of viral types would have enormous market potential. However, almost all of the commercially available therapies are specific for particular viruses. The few broad-spectrum drugs are effective only against a limited number of viral types. They can also cause debilitating side effects, limiting the dosages to suboptimal levels. A broad spectrum antiviral therapy is essentially absent in the current marketplace, and few broad-spectrum antivirals are past the preclinical stage. Therapeutic approaches to treat a wide range of pathogenic viruses are therefore highly desirable.


Related Materials



Additional Technologies by these Inventors


Tech ID/UC Case

29043/2016-99I-0


Related Cases

2016-99I-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備